A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: Effects on some new emerging biomarkers of cardiovascular risk

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Derosa, Giuseppe ^a   Mugellini, Amedeo ^a   Pesce, Rosa M ^a   D'Angelo, Angela ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acetylsalicylic acid; Amlodipine; Cardiovascular risk; Hypertension; New emerging biomarkers; Primary prevention

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ADIPONECTIN; AMLODIPINE; BIGUANIDE; C REACTIVE PROTEIN; CD40 LIGAND; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INTERLEUKIN 1BETA; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MYELOPEROXIDASE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TUMOR NECROSIS FACTOR; VILDAGLIPTIN; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; EPIGASTRIC PAIN; EPISTAXIS; EXERCISE; FEMALE; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BIOMARKERS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; ITALY; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84988971667     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0254-8     Document Type: Article

References (34)

1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311-321
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2):434-444
3. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA et al (2006) Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database. Diabetologia 49(12):2859-2865
4. Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M et al (2013) MIND.IT Study Group. Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial. Diabetes Care 36(9):2566-2572
5. http://www.aemmedi.it/news/single/1/standard_italiani_per_la_cura_del_diabete_mellito_2014/. Accessed Jan 2015
6. American Diabetes Association (2015) Standards of medical care in diabetes-2015. Diabetes Care 38(Suppl 1):S1-S94
7. Sirois C, Couture J, Grégoire JP (2012) Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks? Ther Adv Drug Saf 3(5):213-226
8. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134-2141
9. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840
10. Derosa G, D'Angelo A, Mugellini A, Pesce RM, Fogari E, Maffioli P (2012) Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr Med Res Opin 28(9):1435-1445
11. Rydén L, Standl E, Bartnik M, VandenBerghe G, Betteridge J, deBoer MJ et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28(1):88-136
12. Rifai N, Tracy RP, Ridker PM (1999) Clinical efficacy of an automated highsensitivity C-reactive protein assay. Clin Chem 45(12):2136-2141
13. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8):941-946
14. Zhang M, Tracey K (1988) The cytokine handbook, 3rd edn. Academic Press, San Diego
15. Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP Jr (2004) Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 61:35-39
16. Morishita K, Kubota N, Asano S, Kaziro Y, Nagata S (1987) Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem 262(8):3844-3851
17. Graf D, Korthäuer U, Mages HW, Senger G, Kroczek RA (1992) Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 22(12):3191-3194
18. Winer BJ (1971) Statistical principles in experimental design, 2nd edn. McGraw-Hill, New York
19. Vaucher J, Marques-Vidal P, Waeber G, Vollenweider P (2014) Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus study). Cytokine 66(2):95-100
20. Rosiak M, Postula M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Czlonkowski A et al (2013) Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study. Cardiol J. 20(5):545-551
21. Takahashi Y, Nishida Y, Nakayama T, Asai S (2013) Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. Cardiovasc Diabetol 12:87
22. Kaplon-Cieslicka A, Postula M, Rosiak M, Peller M, Kondracka A, Serafin A et al (2014) Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirintreated patients with type 2 diabetes: an observational study. Cardiovasc Diabetol 13:112
23. Irons BK, Trujillo A, Seifert CF, Simoni JS, Doctolero S, Abo-Salem E et al (2013) Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. J Cardiovasc Pharmacol Ther 18(5):427-432
24. Tanaka M, Nishimura R, Nishimura T, Kawai T, Meguro S, Irie J et al (2014) Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients. Diabetol Metab Syndr 6:56
25. Khan BV, Merchant N, Rahman ST, Ahmad M, Parrott JM, Umar K et al (2013) Changes in central aortic pressure, endothelial function and biomarkers in hypertensive african-americans with the cardiometabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan. Cardiorenal Med 3:221-231
26. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231(25):232-235
27. Flower RJ (1974) Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 26(1):33-67
28. Reilly IA, FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69(1):180-186
29. Hennekens CH, Sechenova O, Hollar D, Serebruany VL (2006) Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther 11(3):170-176
30. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A et al (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17(3-4):317-327
31. Weissmüller T, Campbell EL, Rosenberger P, Scully M, Beck PL, Furuta GT et al (2008) PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cellexpressed ecto-NTPDases. J Clin Invest 118(11):3682-3692
32. Clària J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92(21):9475-9479
33. Grilli M, Pizzi M, Memo M, Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274(5291):1383-1385
34. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T et al (2009) Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183(3):2089-2096